GSK announces FDA advisory committee votes in favour of positive benefit/risk profile for belantamab mafodotin for patients with relapsed/refractory multiple myeloma

FDA ODAC voted 12-0 in favour of the demonstrated benefit of monotherapy treatment with belantamab mafodotin